IMPACT & STRATEGY

The Challenge

mRNA technologies have demonstrated transformative potential, but access remains uneven because of:

Limited manufacturing capacity in low- and middle-income countries (LMICs)
Costly key raw materials and chemicals
High production costs

Our Role

Green Lipids enables decentralized ionizable lipid manufacturing by providing essential components that can be integrated into LMIC mRNA vaccine and therapeutics production. The technology is also applicable to research and product development requiring transfection.

Our Vision

To become a leading provider of affordable ionizable lipids, produced using environmentally responsible principles, that are required for RNA medicines

Strategic Alignment

Our work aligns with significant global health initiatives:

Medicines Patent Pool, South African Medical Research Council (SAMRC) and WHO mRNA technology transfer programme (https://medicinespatentpool.org/what-we-do/mrna-technology-transfer-programme)
South African vaccine manufacturing capacity development of the German Agency for International Cooperation (GIZ) (https://www.giz.de/en/projects/impfstoffe-fur-afrika-verteilung-und-produktion-sudafrika-savax).
Africa CDC goal of 60% local continental vaccine manufacturing by 2040 (https://africacdc.org/thematic-area/african-vaccine-manufacturing/)
Global pandemic preparedness frameworks (e.g. CEPI https://cepi.net/)

Impact Areas

Pandemic Preparedness

Rapid access to lipid components of LNPs enables faster responses to emerging threats

Endemic Disease Solutions

Supports development of vaccines and therapeutics for diseases such as:

Tuberculosis
HIV
Hepatitis B

Regional Economic Development

Use of local supply chains
Skills development
Industrial growth

ESG Commitment

Environmental
Use of renewable feedstocks that potentially reduces the carbon footprint

Social
Capacity development and improved access to valuable technologies in underserved regions

Governance
Transparent, partnership-driven commercial model